Table 3.
Autologous hematopoietic cell transplantation for follicular lymphoma that has undergone histological transformation to large cell lymphoma.
| Author (year) | Number of patients | Age (range) | Conditioning regimen | TRM | PFS | OS | Comments |
|---|---|---|---|---|---|---|---|
| Friedberg et al. [56] (1999) | 21 | 44 (29–58) |
TBI/CY | NA | 46% (5 years) |
58% (5 years) |
All had minimal disease state. Purged autograft used. |
|
| |||||||
| Chen et al. [58] (2001) | 25a | 48 (36–64) |
Mel/TBI/VP | 28% | 36% (5 years) |
37% (5 years) |
All had chemosensitive disease. |
|
| |||||||
| Williams et al. [57, 61] (2001) | 50 | 40 (26–52) |
Various regimens | 8% (100 days) |
30% (5 years) |
51% (5 years) |
100% had chemo-sensitive disease. High LDH led to poor outcomes. |
|
| |||||||
| Hamadani et al. [59] (2008) | 24 | 56 (47–68) |
BU/CY BCNU based |
8% (100 days) |
40% (3 years) |
52% (3 years) |
17% had bulky disease and no purged autografts used. |
|
| |||||||
| Eide et al. [60] (2011) | 30b | 55 (31–65) |
BEAM | NA | 32% (5 years) |
47% (5 years) |
The only prospective trial. All 30 had chemosensitive disease. |
Abbreviations: TBI: total body irradiation; CY: cyclophosphamide; Mel: melphalan; VP: etoposide; BU: busulfan; BCNU: carmustine; TRM: treatment-related mortality; PFS: progression-free survival; OS: overall survival; LDH: lactate dehydrogenase; BEAM: BCNU, etoposide, cytarabine, melphalan.
aOf the 35 patients in the sample, only 25 had true histological transformation to diffuse large B-cell lymphoma. bOf the 47 patients enrolled, only 30 underwent autologous hematopoietic cell transplantation.